AbbVie stated that its net revenues (after discounts and rebates) for its adalimumab brand Humira® was $18.6 billion in 2022. The first adalimumab biosimilar was launched in January 2023, and the majority of the pack launched in July 2023. After 18 months of biosimilar availability in the drug class, utilization of adalimumab biosimilars has only … Continue reading 18 Months of US Adalimumab Biosimilar Competition Yields $11 Billion in Savings